Clinical trials: Coagulation
Opioid Pain Medication
Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
This study is a prospective randomized trial examining the effect of topically combined antifibrinolytics (Tranexamic acid) with local anesthetics in all electively created surgical wound beds in hand surgery to provide long term…
- Trial name
- NCT04814433
- Testing
- Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Severe Hemophilia A
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
This study was divided into four stages: screening period, main trial period, extension period and follow-up period. In the main trial, both groups received FRSW107 prophylactic therapy.
- Trial name
- NCT06136507
- Testing
- FRSW107
- Where
- 13 sites in China
- Volunteers
- 76 people
- Sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Hemodialysis Complication
Strategies for Asymmetrical Triacetate Dialyzer Heparin-Free Effective Hemodialysis
Not all dialysis patients tolerate heparin anticoagulation. Heparin should be avoided in patients at high risk of bleeding. Strategies include saline infusion, citrate-containing dialysate, regional citrate anticoagulation and…
- Trial name
- SAFE (NCT04381234)
- Testing
- dialyzer, hemodialysis with citrate-containing dialysate, predilution hemodiafiltration
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Von Willebrand Disease
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
The main objective of the study is to compare the pharmacokinetics of Optivate® with the subject's current FVIII concentrate when given as a bolus dose of 50IU/kg.
- Trial name
- NCT02246881
- Testing
- Optivate® (Human Coagulation Factor VIII)
- Where
- 8 sites in Poland, United Kingdom
- Sponsor
- Bio Products Laboratory
Humoral Rejection, Guillain-Barre Syndrome
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels.
- Conditions
- Humoral Rejection, Guillain-Barre Syndrome, Miller Fisher Syndrome, CIDP
- Trial name
- NCT03801135
- Testing
- Fibrinogen concentrate, Fresh Frozen Plasma
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- University Medical Centre Ljubljana
Idiopathic Thrombocytopenia Purpura
A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability (BA) of two lots of E5501 40 mg tablets administered twice as single oral doses to healthy subjects.
- Trial name
- NCT01289509
- Testing
- E5501, Drug: E5501
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Hemophilia A
A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.
This study is about a factor VIII medicine called Adynovate (TAK-660) used during surgery for people with hemophilia A who have low blood levels of factor VIII.
- Trial name
- NCT04941898
- Testing
- PEGylated Recombinant Factor VIII
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Takeda
Renal Disorder Associated With Type II Diabetes Mellitus
Type 2 Diabetes Mellitus and Chronic Kidney Disease
To investigate the effect of co existance of diabetes mellitus and chronic kidney disease on basic coagulation profile in comparison with diabetic patients with normal kidney function and non diabetic patients with chronic kidney…
- Trial name
- NCT04971252
- Testing
- Hematologic tests for patients with diabetes mellitus and chronic kidney disease
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Disorders of Coagulation
Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery
The purpose of this study is to investigate the effect of thin fluid with starch versus thin fluid without starch on coagulation in elective surgery when the patient is normovolæmic during operation.
- Trial name
- NCT02009033
- Testing
- Lactated Ringer, Hydroxyethylstarch
- Volunteers
- 40 people
- Sponsor
- K. C. Rasmussen
Multiple Sclerosis
Evaluation of Coagulation in Multiple Sclerosis
Recent research in multiple sclerosis (MS) have suggested that altered coagulation and vascular inflammation may play a role in pathophysiology of MS. Sonoclot is viscoelastic method of analyzing clot formation.
- Trial name
- NCT01711255
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Bastyr University
Neoplasms, Thrombosis
THrombo-Embolic Event in Onco-hematology
The overall incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) is 1 per 200 cancer patients, about 5 times higher than in the general population.
- Conditions
- Neoplasms, Thrombosis, Coagulation Disorder
- Trial name
- THEO (NCT03826043)
- Testing
- Blood sample analysis
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Centre Antoine Lacassagne
Von Willebrand Disease
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Multicenter, prospective, non-controlled study in a pediatric cohort (<6 years-old) with severe (type 2 or 3) hereditary Von Willebrand Disease (VWD).
- Trial name
- NCT02472665
- Testing
- plasma-derived FVIII/VWF concentrate
- Where
- 4 sites in Spain
- Sponsor
- Grifols Therapeutics LLC
Essential Thrombocythaemia
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
Age related differences in response to a drug could arise from variation in pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles between age groups.
- Trial name
- NCT00413634
- Testing
- anagrelide hydrochloride
- Where
- 5 sites in Spain, Sweden and 1 more
- Volunteers
- 24 people
- Sponsor
- Shire
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Severe Hemophilia A, Osteoporosis
Bone Microarchitecture in Men With Hemophilia
Hemophilia A and B are hereditary sex-linked deficiencies of coagulation factors VIII and IX characterized by bleeding. Their modern therapy increases life expectancy and risk of age-related diseases, e.g., osteoporosis.
- Trial name
- HEMOS (NCT05127681)
- Testing
- HR-pQCT, Blood sample, Dual energy X-ray absorptiometry
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
Factor IX Deficiency
Natural History Study of Factor IX Treatment and Complications
This study will examine two groups of subjects with factor IX (FIX) deficiency: 1) those with a current or history of inhibitors to FIX, and; 2) groups of two or more affected brothers, with or without inhibitors.
- Trial name
- B-Natural (NCT02502409)
- Testing
- Standard care with blood and urine sample collection
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Skane University Hospital
Respiratory Depression, Blood Pressure
Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust
The US EPA Clean Air Multiyear research program is moving toward a multi-pollutant approach to the assessment of air pollution in response to recommendations by the NRC 2004 and the BOSC in 2005.
- Trial name
- DEPOZ (NCT01874834)
- Testing
- ozone
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Environmental Protection Agency (EPA)
Thrombosis, Blood Coagulation Disorder
Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)
Consenting patients with end-stage heart failure that are implanted with/candidates for implant of a short-term/durable mechanical circulatory support device (e.g.: percutaneous microaxial pumps (Impella), extracorporeal membrane…
- Conditions
- Thrombosis, Blood Coagulation Disorder, Platelet Thrombus, Platelet Dysfunction Due to Aspirin
- Trial name
- PASVAD (NCT03255928)
- Testing
- PAS assay, TGT
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Scientific Institute San Raffaele
Chronic Myeloproliferative Disorders, Leukemia
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
Patients are being asked to participate in this study because they have a malignant blood disease such as Myelodysplastic Syndrome (MDS), Myeloproliferative Disorder (MPD), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes
- Trial name
- MPDMDSBMT (NCT00069992)
- Testing
- Total Body Irradiation, Fludarabine, Campath 1H
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Baylor College of Medicine
Hemophilia
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
Primary Objective: To characterize the frequency of bleeding episodes (BE) while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor concentrate or bypassing agent (BPA)…
- Trial name
- ATLAS-PPX (NCT03549871)
- Testing
- Fitusiran, BPA prophylaxis, Factor (FVIII or FIX) prophylaxis
- Where
- 35 sites in United States, Australia and 13 more
- Volunteers
- 80 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.